IMMUNOPHOTONICS
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a strategic partnership with Veterinary Cancer Therapeutics, LLC. The company was founded in 2008 and is based in Columbia, Missouri.
IMMUNOPHOTONICS
Industry:
Biotechnology Health Care Life Science
Founded:
2008-01-01
Address:
Columbia, Missouri, United States
Country:
United States
Website Url:
http://www.immunophotonics.com
Total Employee:
1+
Status:
Active
Contact:
636-675-6161
Total Funding:
26.9 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Zubizoom Investments
Zubizoom Investments investment in Series B - ImmunoPhotonics
iSELECT FUND
iSELECT FUND investment in Series B - ImmunoPhotonics
Immune
Immune investment in Series B - ImmunoPhotonics
ROVAQ Ventures
ROVAQ Ventures investment in Series B - ImmunoPhotonics
National Cancer Institute
National Cancer Institute investment in Grant - ImmunoPhotonics
Tech Coast Angels
Tech Coast Angels investment in Venture Round - ImmunoPhotonics
St. Louis Arch Angels
St. Louis Arch Angels investment in Series A - ImmunoPhotonics
Missouri Technology Corporation
Missouri Technology Corporation investment in Series A - ImmunoPhotonics
iSELECT FUND
iSELECT FUND investment in Series A - ImmunoPhotonics
BioGenerator
BioGenerator investment in Series A - ImmunoPhotonics
Official Site Inspections
http://www.immunophotonics.com Semrush global rank: 5.82 M Semrush visits lastest month: 1.43 K
- Host name: web2.axxiem.com
- IP address: 34.230.198.252
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "ImmunoPhotonics"
About - Immunophotonics
Immunophotonics is a privately owned clinical-stage biotech company that is pioneering the burgeoning field of Interventional Immuno-OncologyTM through the development of novel …See details»
ImmunoPhotonics - Crunchbase Company Profile
ImmunoPhotonics develops immunotherapy-based treatments for cancer. A minimally invasive therapeutic cancer vaccine for the treatment of metastatic …See details»
Immunophotonics Company Profile 2024: Valuation, Funding
Immunophotonics General Information Description. Developer of a proprietary carbohydrate polymer designed to transform tumor ablation into hypnotherapy for cancer. The company's …See details»
Immunophotonics, Inc. - Org Chart, Teams, Culture
ImmunoPhotonics has a strategic partnership with Veterinary Cancer Therapeutics, LLC. The company was founded in 2008 and is based in Colu... Read more. Industries. Biotechnology, Health Care. Stage. Venture. …See details»
Immunophotonics, Inc
Immunophotonics is a US-based privately owned clinical stage (Phase 1/2) biotech company developing a first-in-class drug (IP-001) to address the major problem of tumor recurrence …See details»
FCOI Policy - Immunophotonics
N I H F C O I P O L I C Y. COMPANY-WIDE POLICY: GRANT FUNDING FINANCIAL CONFLICT OF INTEREST DISCLOSURES. SCOPE: Company Wide. Immunophotonics, Inc. …See details»
Immunophotonics - Products, Competitors, Financials, Employees ...
Immunophotonics operates as a clinical-stage biotech company focused on developing a novel class of therapeutics in the immuno-oncology sector. Use the CB Insights Platform to explore …See details»
Immunophotonics, Inc. | European Clinical Trials Information …
Over the years, Immunophotonics has received several rounds of funding and grants to support its research and development efforts. In 2019, the company secured $2.53 million in funding …See details»
ImmunoPhotonics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Tomas Hode, PhD - President, Chief Innovation Officer, …
Immunophotonics is a privately owned clinical-stage biotech company based in St. Louis, Missouri, with subsidiaries in Bern, Switzerland, and Tianjin, China.See details»
Immunophotonics Inc. - Company Profile & Staff Directory
Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently …See details»
PIONEERING INTERVENTIONAL IMMUNO-ONCOLOGY TM
Immunophotonics.com IRimmunophotonics.com US: 1 (314) 67-019 CH: 41 79 343 493 Industry: Therapeutics, Oncology Stage: Clinical phase 2a, safety & tolerability confirmed in phase 1b …See details»
Immunophotonics - Overview, News & Similar companies
Dec 20, 2023 Immunophotonics, Inc. is a privately owned, clinical-stage biotech company pioneering the emerging field of Interventional Immuno-Oncology. IP-001, the first asset from …See details»
ImmunoPhotonics - Contacts, Employees, Board Members, …
Organization. ImmunoPhotonics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... About. ImmunoPhotonics has 5 current …See details»
Immunophotonics, Inc. Information - RocketReach
Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently …See details»
Immunophotonics, Inc. - Drug pipelines, Patents, Clinical trials
Immunophotonics will also be holding one-on-one investor meetings throughout the day. Interested investors can register to attend and schedule on-on-one meetings here. ... The …See details»
News & Media - Immunophotonics
Oct 1, 2024 Lu Alleruzzo, CEO and David Anderson, PhD, CSO of Immunophotonics, are excited to participate in the NCI SBIR Peer Learning... Read More . November 5, 2024 …See details»
Pipeline - Immunophotonics
IP-001 A novel cationic immune stimulant The first asset from Immunophotonics’ broad intellectual property portfolio. IP-001 Oncology Transforming tumor ablations into a systemic …See details»
News Archive - Immunophotonics
Oct 1, 2024 Immunophotonics is excited to share that Wei Chen, co-inventor of IP-001, Stephenson Chair, professor and interim director of the Stephenson School of Biomedical …See details»